Advertisement

Topics

Otsuka Pharmaceutical to Acquire Neurovance, Inc.

16:05 EST 2 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Acquisition of clinical-stage company in ADHD widens Otsuka’s presence in mental health Otsuka Pharmaceutical Co., Ltd. (OPC) today announces an agreement with Neurovance, Inc. (Neurovance) under which OPC has agreed to ac...

Other Sources for this Article

Otsuka Contacts
Media:
Otsuka Pharmaceutical Co., Ltd.
Jeffrey Gilbert, +81 3 6361 7379
Leader, Pharmaceutical PR
Mobile: +81 80 8728 6039
gilbert.jeffrey@otsuka.co.jp
U.S.
Otsuka America Pharmaceutical, Inc.
Kimberly Whitefield, +1 609 535-9259
Corporate Communications
kimberly.whitefield@otsuka-us.com

NEXT ARTICLE

More From BioPortfolio on "Otsuka Pharmaceutical to Acquire Neurovance, Inc."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...